It was to the “deep frustration” of research director Mads Krogsgaard Thomsen that Novo Nordisk gave up on a year long project to develop an insulin pill, that would have given type 1 diabetics a needle-free alternative, in 2016.
The pill had been predicted to have a future as one of the world’s best-selling medicines, with potential sales of up to USD 10 billion a year, if Novo Nordisk could develop it to be market-ready.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.